Company profile: Reapplix

1.1 - Company Overview

Reapplix

Headquarter: Denmark

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of biological wound therapies that identify, isolate, and reapply blood-derived proteins to improve healing in chronic wounds, including the 3C Patch System made entirely from the patient’s own blood to accelerate healing of diabetic foot ulcers.

Products and services

Blood-Derived Protein Identification: Research-grade program that identifies blood-derived proteins that improve wound healing, focusing on chronic wounds and enabling precise selection of therapeutic factors for autologous application
3C Patch System: Autologous biological wound therapy product made entirely from the patient’s own blood, engineered to accelerate healing of diabetic foot ulcers by reapplying beneficial proteins to the wound
Protein Isolation and Preparation: Laboratory-scale service that isolates identified blood-derived proteins for reapplication to patients with chronic wounds, supporting improved wound healing.

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Reapplix

Intelligent Bio Solutions

HQ: United States Website

Description: Provider of diagnostic solutions, offering the Intelligent Fingerprinting Drug Screening System—a portable test that detects recent drug use via fingerprint sweat with results in under ten minutes—and a printable OTFT-based biosensor platform for real-time, non-invasive diagnostic tests adaptable to various health conditions.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Intelligent Bio Solutions company profile →

Tandem Diabetes Care

HQ: United States Website

Description: Provider of insulin delivery solutions including the t:slim X2 insulin pump with color touchscreen that pairs with multiple CGM sensors and uses Control-IQ technology for automated insulin delivery; the Tandem Mobi System, a compact pump controllable via a compatible iPhone; Control-IQ Technology adjusting insulin based on CGM readings with automatic correction boluses and activity settings; infusion sets; and remote software updates.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Tandem Diabetes Care company profile →

CanAm Care

HQ: United States Website

Description: Provider of medical equipment and devices as a healthcare company, engaged in manufacturing and retail.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full CanAm Care company profile →

Serodus

HQ: Norway Website

Description: Provider of Scandinavian drug development focused on unmet needs in diabetes and diabetic comorbidities. In-licenses early-stage candidates and partners after Phase II proof of clinical effect. Pipeline includes SER150, an anti-inflammatory targeting diabetic kidney disease via thromboxane synthase inhibition and receptor blockade, and SER140, an IL-1β receptor antagonist for diabetic kidney disease.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Serodus company profile →

Thermalin

HQ: United States Website

Description: Provider of insulins and delivery systems that transform the economic, treatment, and disease management paradigms for diabetes.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Thermalin company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Reapplix

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Reapplix

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Reapplix's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Reapplix's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Reapplix

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Reapplix's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Reapplix's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Reapplix

4.2 - Public trading comparable groups for Reapplix

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Reapplix

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Reapplix

What does Reapplix do?

Reapplix is a provider of biological wound therapies that identify, isolate, and reapply blood-derived proteins to improve healing in chronic wounds, including the 3C Patch System made entirely from the patient’s own blood to accelerate healing of diabetic foot ulcers.

Who are Reapplix's competitors?

Reapplix's competitors and similar companies include Intelligent Bio Solutions, Tandem Diabetes Care, CanAm Care, Serodus, and Thermalin.

Where is Reapplix headquartered?

Reapplix is headquartered in Denmark.

How many employees does Reapplix have?

Reapplix has 1,000 employees 🔒.

When was Reapplix founded?

Reapplix was founded in 2010 🔒.

What sector and industry vertical is Reapplix in?

Reapplix is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Reapplix

Who are the top strategic acquirers in Reapplix's sector and industry

Top strategic M&A buyers and acquirers in Reapplix's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Reapplix?

Top strategic M&A buyers groups and sectors for Reapplix include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Reapplix's sector and industry vertical

Which are the top PE firms investing in Reapplix's sector and industry vertical?

Top PE firms investing in Reapplix's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Reapplix's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Reapplix's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Reapplix's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Reapplix include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Reapplix's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Reapplix?

The key public trading comparables and valuation benchmarks for Reapplix include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Reapplix for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Reapplix with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Reapplix's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Reapplix with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Reapplix's' sector and industry vertical?

Access recent funding rounds and capital raises in Reapplix's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Reapplix

Start Free Trial Book a Demo